Drilling down on drug prices
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Value |
|---|---|---|---|
| LDR | 00000cab a2200000 4500 | ||
| 001 | MAP20190021326 | ||
| 003 | MAP | ||
| 005 | 20190715150850.0 | ||
| 008 | 190710e20190507usa|||p |0|||b|eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 084 | $a931 | ||
| 100 | 1 | $0MAPA20190009621$aPasswater, Keith | |
| 245 | 0 | 0 | $aDrilling down on drug prices$cKeith Passwater, Dave Nelson |
| 300 | $a8 p. | ||
| 520 | $aExtending life and improving quality of life for literally millions, drug treatments such as aspirin, penicillin, insulin, AZT, cancer drug Herceptin, Harvoni, and Lipitor are nothing short of miracle drugs. Recently developed therapies are also impressive, such as single-dose Kymriah, which has an unprecedented 83 percent remission rate for children with acute lymphoblastic leukemia.[1] Another example is the newly available gene therapy Luxturna, which can cure blindness in carefully selected patients. Such therapies can achieve outcomes that are truly miraculous for those cured patients; they can also be staggeringly expensive. While anyone with a heart would agree that these miracle drug benefits are wonderful for patients, we need to find ways to harness these invaluable benefits while also finding ways to curb the growth in drug costs in the U.S. for all partiesconsumers, payers, and manufacturers alike. | ||
| 650 | 4 | $0MAPA20080606633$aIndustria farmacéutica | |
| 650 | 4 | $0MAPA20080579784$aCostes económicos | |
| 650 | 4 | $0MAPA20080621919$aPrecios de los medicamentos | |
| 700 | 1 | $0MAPA20080051983$aNelson, Dave | |
| 773 | 0 | $wMAP20190020794$tContingencies : American Academy of Actuaries$dWashington : American Academy of Actuaries, 2019-2024$g07/05/2019 Año 2019 - May-June , p. 38-45 |